Keros Therapeutics, Inc. · NASDAQ:KROS
Keros Therapeutics — Investor Presentation (August 2026)
24 slides from Keros Therapeutics's investor presentation, August 2026
Slide 1: Corporate Presentation August 2026
Corporate Presentation August 2026
Slide 2: Disclaimer
Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “poten
Slide 3: Focused on Transforming the Lives of a Wide Range of Patients with TGF-β Disorders
Focused on Transforming the Lives of a Wide Range of Patients with Disorders Linked to Dysfunctional TGF-β Superfamily Signaling Keros is a clinical-stage biopharmaceutical company We believe our product candidates have the Developing potentially differentiated product candidates designed potential
Slide 4: Rinvatercept (KER-065)
Rinvatercept (KER-065) Corporate Presentation 4
Slide 5: Rinvatercept (KER-065)
Rinvatercept (KER-065) ▪ Rinvatercept is an investigational modified activin receptor type II ligand trap ▪ Rinvatercept is designed to bind and inhibit TGF-ß ligands, including activin A and myostatin, which are negative regulators of muscle and bone mass and strength, to: • Improve skeletal muscle
Slide 6: Rinvatercept: Potential to Treat a Broad Range of Neuromuscular Diseases
Rinvatercept: Potential to Treat a Broad Range of Neuromuscular Diseases ▪ Neuromuscular disorders arise from: • Mutations in genes coding for structural proteins that are unable to connect the contractile apparatus to the basal lamina o Examples: DMD, BMD, LGMD and CMD • Failure of transmission of
Slide 7: Rinvatercept: Duchenne Muscular Dystrophy (DMD)
Rinvatercept: Duchenne Muscular Dystrophy (DMD) Corporate Presentation 7
Slide 8: Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy (DMD) ▪ DMD is a rare, severe and ultimately fatal genetic DMD Disease Progression4,5 disease characterized by the absence of dystrophin protein, leading to progressive muscle degeneration and weakness ▪ The National Organization for Rare Disorders estimates that approxim
Slide 9: Current Treatment Landscape for DMD
Current Treatment Landscape for DMD Glucocorticoids Exon Skipping Gene Therapy HDAC Inhibitors • Help to maintain • Four therapies • FDA granted • Modulate the muscle function in approved by the FDA, ELEVIDYS® full deregulated activity of DMD patients each addressing a approval for the HDACs in dyst
Slide 10: Robust Preclinical Data Suggests Potential Benefits of Rinvatercept
Robust Preclinical Data Suggests Potential Benefits of Rinvatercept Inhibition of both activins and ▪ Offer muscle, bone and fat benefits: Potential to increase muscle mass, decrease fat mass and improve BMD, based on preclinical data and prior myostatin can experience with ActRIIB-Fc and Keros mole
Slide 11: Treatment with Rinvatercept Was Generally Well Tolerated in Phase 1 Healthy Volunteer Trial
Treatment with Rinvatercept Was Generally Well Tolerated in Phase 1 Healthy Volunteer Trial We completed a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single (1.0 mg/kg, 3.0 mg/kg and 5.0 mg/kg) and multiple (1.25 mg/kg and 2.0 mg/kg) ascending doses of
Slide 12: Phase 1 Healthy Volunteer Data Support Potential for Rinvatercept to Address Multiple Aspects of DMD
Phase 1 Healthy Volunteer Data Support Potential for Rinvatercept to Address Multiple Aspects of DMD Muscle Bone Fat In DMD, the replacement of muscle fibers with Reduced muscle strength, loss of ambulation Decreased mobility and the use of fatty and fibrotic tissue leads to progressive and use of g
Slide 13: Rinvatercept: Phase 2 Clinical Trial Design
Rinvatercept: Phase 2 Clinical Trial Design We have initiated an open-label, multi-cohort Phase 2 basket clinical trial to evaluate rinvatercept in patients with DMD and we expect to report initial data from this trial in the first half of 2027 Intra-Patient Dose Screening Period Escalation* Safety
Slide 14: Rinvatercept: Amyotrophic Lateral Sclerosis (ALS)
Rinvatercept: Amyotrophic Lateral Sclerosis (ALS) Corporate Presentation 14
Slide 15: Rinvatercept and ALS: A Novel Approach
Rinvatercept and ALS: A Novel Approach ▪ ALS is a progressive, neurodegenerative disease that destroys motor neurons, leading to muscle weakness, loss of function and eventually paralysis1 ▪ In the U.S. alone, ALS has a prevalence of ~9.9 per 100,000 people, with ~33K people estimated to have been l
Slide 16: Third-Party Product Candidate (Apitegromab) Phase 3 Data Demonstrated Muscle Preservation Can Provide Benefit
Third-Party Product Candidate (Apitegromab) Phase 3 Data Demonstrated That Muscle Preservation Can Provide Benefit Motor neuron loss is a hallmark of both spinal muscular atrophy (SMA) and ALS ▸ Apitegromab, a third-party product candidate being developed for the treatment of SMA, established proof-
Slide 17: Potential Benefits of Rinvatercept Treatment for Individuals with ALS
Potential Benefits of Rinvatercept Treatment for Individuals with ALS • Skeletal muscle is potentially an active participant in ALS pathology, instead of a passive victim of motor neuron degeneration1 • By promoting muscle growth and function, rinvatercept has the potential to: ▸Counteract muscle at
Slide 18: RKER-065 Treatment Preserved Muscle Strength and Neuromuscular Transmission in a Mouse Model of ALS
RKER-065 Treatment Preserved Muscle Strength and Neuromuscular Transmission in a Mouse Model of ALS Grip Strength Motor Unit Function ✱ (Repetitive Nerve Stimulation, RNS 10 Hz) ✱✱✱✱ ✱✱ 105 WT: Vehicle 0.20 SOD1: Vehicle SOD1: RKER-065 Grip Strength (kg) 0.15 100 % Decrement 0.10 95 ** **** 0.05 90
Slide 19: RKER-065 Treatment Protected the Neuromuscular Junction in a Mouse Model of ALS
RKER-065 Treatment Protected the Neuromuscular Junction in a Mouse Model of ALS SOD1-G93 Mouse Model of ALS In healthy neuromuscular junctions (NMJs), there is a normal complement of neurofilaments at the axon terminal However, in certain neuromuscular disorders like ALS, there is a deficit of neuro
Slide 20: Elritercept (KER-050)
Elritercept (KER-050) Investigational Treatment for Anemia and Thrombocytopenia in Patients with Myelodysplastic Syndromes and in Patients with Myelofibrosis Corporate Presentation 20
Slide 21: Global License Agreement with Takeda Pharmaceuticals
Global License Agreement with Takeda Pharmaceuticals On December 3, 2024, Keros announced it had entered into an exclusive license agreement with Takeda to develop, manufacture and commercialize elritercept globally, other than mainland China, Hong Kong, and Macau Financials: • Keros received an upf
Slide 22: RENEW Trial: Ongoing Phase 3 Clinical Trial to Evaluate Elritercept in Patients with MDS
RENEW Trial: Ongoing Phase 3 Clinical Trial to Evaluate Elritercept in Patients with MDS • Based on data from our Phase 2 clinical trial of elritercept in patients with MDS, a global, multicenter, double-blind, randomized, placebo-controlled Phase 3 RENEW clinical trial was initiated to evaluate the
Slide 23: Proprietary Discovery Approach
Proprietary Discovery Approach Corporate Presentation 23
Slide 24: Proprietary Discovery Approach
Proprietary Discovery Approach • Keros has a broad approach to target the TGF-β superfamily to develop product candidates with the potential to treat a broad range of indications, including neuromuscular and neurodegenerative disorders, rare bone and fibrosis diseases and obesity/frailty • Large lib
Keros Therapeutics — Investor Presentation (August 2026) on 6ix